3 million medical representatives, where will the future go?

Since the first half of this year, many hospitals have turned down daily visits from medical representatives due to special periods.
and with the introduction of new regulations, and let hospitals more reject potential risks, the pharmaceutical industry reported, layoffs, pay cuts and other news.
, in the context of the dynamic adjustment of the medical insurance catalogue, price negotiations, centralized procurement of drugs and other medical reforms and the intensity of medical anti-corruption efforts, the living space of medical representatives has become smaller and smaller.
3 million medical representatives, where will the future go? It is understood that medical representatives are generally divided into "straight camp" and "agent" two categories.
Among them, directly-employed pharmaceutical representatives directly belong to enterprises, previously mostly foreign enterprises, and now domestic enterprises also have a large number of direct-employed personnel;
, the direct-camp personnel of foreign enterprises are the true meaning of the domestic road at the beginning.
they are mainly engaged in professional academic promotion, the main role is to help doctors understand the efficacy and advantages of drugs, so that doctors in the prescription of drugs to consider their agents of drugs.
Compared with foreign enterprises, domestic enterprises because of their own product efficacy research is not in-depth enough, pharmaceutical representatives can not be academic promotion, and such as acting as a pharmaceutical representative, it is more difficult to help doctors in the medical business.
this year, the National Health and Wellness Commission and other departments on medical corruption intensive text, and from August, the country into the hospital inspection period, medical institutions practitioners to accept kickbacks and other corrupt practices to focus on combating.
September 16, the National Health Insurance Administration issued "guidance on the establishment of pharmaceutical prices and credit evaluation system", which is known as the industry's "industry blacklist system."
under this system, once pharmaceutical companies are investigated for illegal acts such as commercial bribery, they become deductions.
the blacklisting of pharmaceutical companies will seriously affect drug sales.
provinces have made it clear that companies that are tainted by bribery will be kicked off the procurement list.
with the promotion of the blacklist system, the industry reports are frequent, the industry chill is coming.
the normalization of collection, many pharmaceutical companies have made the decision to lay off pharmaceutical representatives, such as Sanofi disbanded the collection of drugs "Porvi" sales team.
in general, the days of pharmaceutical representatives "lying down to make money" are long gone, and the industry will have less and less room to live.
, will the 3 million medical representatives disappear in the future? In the view of many pharmaceutical representatives, industry reshuffle is inevitable, but pharmaceutical representatives will not disappear on a large scale.
, many pharmaceutical companies, including multinational pharmaceutical companies, are targeting the grass-roots market and the out-of-hospital market, they still need a large number of pharmaceutical representatives.
from the deep grass-roots, expand the sales team of pharmaceutical companies, it offset some of the impact of mining, performance achieved significant growth.
, for example, Pfizer launched the County Hospital Project in 2016, allegedly expanding its sales force to more than a thousand people.
In the first half of this year, Pfizer's "Lipto", "Live Joy" and other core products, although not in the collection, but responsible for the sales of these varieties of Pfizer strong performance has bucked the trend, year-on-year growth of 17% in the second quarter, which is closely related to its development of grass-roots markets.
Is unique, Novartic announced on September 9 this year with the "China County Hospital Deans Alliance" to jointly develop the grass-roots cardiovascular disease field market, the company currently has more than 3000 people in the Midwest grass-roots market sales team, the company's 2020 half-year report shows that china's market revenue of $2.659 billion, up 14% year-on-year.
long term, the traditional marketing model of pharmaceutical companies is being hit.
background, the key to the survival of pharmaceutical representatives is to return to its essence, focus on purely academic promotion, and increase compliance and safety awareness.